Vito Palombella

Vito Palombella

Director/Board Member at MOLECULAR PARTNERS AG

Net worth: 35 101 $ as of 30/06/2026

64 year
Health Technology
Consumer Services
Finance

Profile

Vito J Palombella is currently Director at Molecular Partners, Inc., Independent Non-Executive Director at Molecular Partners AG since 2020, Advisor at Atlas Venture Advisors, Inc., and Chief Scientific Officer at TRIANA Biomedicines, Inc. since 2023.
Formerly, Dr. Palombella was Senior Director-Cell & Molecular Biology at Millennium Pharmaceuticals, Inc. from 1999 to 2000, Senior Director-Cell & Molecular Biology at LeukoSite, Inc., Director-Molecular Biology & Protein Chemistry at Bioverativ Therapeutics, Inc. from 2000 to 2004, Chief Scientific Officer & Executive VP at Infinity Pharmaceuticals, Inc. from 2015 to 2016, and Chief Scientific Officer at Surface Oncology, Inc. from 2016 to 2023.
Education includes undergraduate studies at Rutgers State University of New Jersey and graduate and doctorate degrees from New York University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/12/2025 9,046 ( 0.02% ) 35 101 $ 30/06/2026

Vito Palombella active positions

CompaniesPositionStart
MOLECULAR PARTNERS AG Director/Board Member 01/04/2020
Director/Board Member -
Consultant / Advisor -
Chief Tech/Sci/R&D Officer 01/09/2023

Former positions of Vito Palombella

CompaniesPositionEnd
SURFACE ONCOLOGY, INC. Chief Tech/Sci/R&D Officer 08/09/2023
INFINITY PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 22/01/2016
Corporate Officer/Principal 01/01/2004
Corporate Officer/Principal 01/10/2000
Corporate Officer/Principal 01/01/1999
See the detail of Vito Palombella's experience

Training of Vito Palombella

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

53

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Vito Palombella